CO5180581A1 - Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia - Google Patents

Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia

Info

Publication number
CO5180581A1
CO5180581A1 CO00066880A CO00066880A CO5180581A1 CO 5180581 A1 CO5180581 A1 CO 5180581A1 CO 00066880 A CO00066880 A CO 00066880A CO 00066880 A CO00066880 A CO 00066880A CO 5180581 A1 CO5180581 A1 CO 5180581A1
Authority
CO
Colombia
Prior art keywords
ischemia
treatment
pharmaceutical
tions
compounds
Prior art date
Application number
CO00066880A
Other languages
English (en)
Inventor
Masamune Hiroko
Michael Paul Denino
Robert William Scott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5180581A1 publication Critical patent/CO5180581A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Agonistas de A3, procedimientos para usar tales agonistas de A3 y composiciones farmacéuticas que contienen tales agonistas de A3. Los agonistas de A3 son útiles para la reducción de lesiones de tejidos producidas por isquemia o hipoxia de los tejidos.<EMI FILE="00066880_1" ID="1" IMF=JPEG >
CO00066880A 1999-09-30 2000-09-05 Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia CO5180581A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15682899P 1999-09-30 1999-09-30

Publications (1)

Publication Number Publication Date
CO5180581A1 true CO5180581A1 (es) 2002-07-30

Family

ID=22561263

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00066880A CO5180581A1 (es) 1999-09-30 2000-09-05 Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia

Country Status (41)

Country Link
EP (1) EP1216257B1 (es)
JP (1) JP2003510331A (es)
KR (1) KR100481605B1 (es)
CN (1) CN1374967A (es)
AP (1) AP2002002458A0 (es)
AR (1) AR029887A1 (es)
AT (1) ATE312117T1 (es)
AU (1) AU778185B2 (es)
BG (1) BG106636A (es)
BR (1) BR0014384A (es)
CA (1) CA2386079A1 (es)
CO (1) CO5180581A1 (es)
CR (1) CR6592A (es)
CZ (1) CZ20021020A3 (es)
DE (1) DE60024649D1 (es)
EA (1) EA005422B1 (es)
EC (1) ECSP003682A (es)
EE (1) EE200200172A (es)
GE (1) GEP20043241B (es)
GT (1) GT200000161A (es)
HK (1) HK1049011A1 (es)
HR (1) HRP20020253A2 (es)
HU (1) HUP0202807A3 (es)
IL (1) IL148222A0 (es)
IS (1) IS6286A (es)
MA (1) MA26822A1 (es)
MX (1) MXPA02003308A (es)
MY (1) MY133996A (es)
NO (1) NO20021474L (es)
NZ (1) NZ517177A (es)
OA (1) OA12021A (es)
PA (1) PA8503301A1 (es)
PE (1) PE20010696A1 (es)
PL (1) PL357371A1 (es)
SK (1) SK4182002A3 (es)
TN (1) TNSN00191A1 (es)
TR (1) TR200200843T2 (es)
UA (1) UA73525C2 (es)
WO (1) WO2001023399A1 (es)
YU (1) YU23102A (es)
ZA (1) ZA200202461B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
EP1241176A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
JP2005511590A (ja) * 2001-11-02 2005-04-28 アベンティス・ファーマスーティカルズ・インコーポレイテツド アデノシンａ１／ａ２アゴニストおよびナトリウム水素交換体阻害剤を含む医薬組成物
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
CN101385738A (zh) * 2002-04-18 2009-03-18 Cv医药有限公司 包括给予A1腺苷激动剂以及β受体阻滞剂、钙通道阻滞剂、或强心苷的治疗心律失常的方法
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
JP2007513082A (ja) * 2003-11-10 2007-05-24 シエーリング アクチエンゲゼルシャフト Ｃｃｒ−５アンタゴニストとして有用なベンジルエーテルアミン化合物
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
JP2008504228A (ja) 2004-03-24 2008-02-14 ファスジェン・リミテッド・ライアビリティ・カンパニー Ａｍｐ活性化プロテインキナーゼの薬理学的阻害による新規神経保護方法
WO2005108360A1 (en) 2004-05-07 2005-11-17 Janssen Pharmaceutica N.V. Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DK1778239T3 (da) * 2004-07-28 2013-12-02 Can Fite Biopharma Ltd Adenosin-a3-receptor-agonister til behandling af sygdomme forbundet medtørre øjne, herunder sjögrens syndrom
EP1781331A1 (en) * 2004-08-09 2007-05-09 Université Catholique de Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
US8563591B2 (en) 2004-08-30 2013-10-22 Janssen Pharmaceutica N.V. Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
JP5208505B2 (ja) 2004-08-30 2013-06-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ １１−ベータヒドロキシステロイドデヒドロゲナーゼ阻害剤としてのｎ−２アダマンタニル−２−フェノキシ−アセトアミド誘導体
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AR058104A1 (es) 2005-10-21 2008-01-23 Novartis Ag Compuestos organicos
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
EP2089393A1 (en) 2006-10-30 2009-08-19 Novartis AG Heterocyclic compounds as antiinflammatory agents
PL2231642T3 (pl) 2008-01-11 2014-04-30 Novartis Ag Pirymidyny jako inhibitory kinazy
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
WO2011010306A1 (en) 2009-07-21 2011-01-27 Ramot At Tel-Aviv University Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
SG178454A1 (en) 2009-08-17 2012-03-29 Intellikine Inc Heterocyclic compounds and uses thereof
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
JP6238969B2 (ja) 2012-05-08 2017-11-29 エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． 新規方法
RU2559776C2 (ru) * 2012-08-20 2015-08-10 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
RU2691951C2 (ru) 2013-11-06 2019-06-19 Аэромикс, Инк. Новые составы
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
RU2611339C2 (ru) * 2014-02-17 2017-02-21 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции с пролонгированным высвобождением для лечения цереброваскулярных расстройств
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
RU2582961C1 (ru) * 2015-03-04 2016-04-27 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции в жидких лекарственных формах для лечения цереброваскулярных расстройств и способы их изготовления
RU2712150C1 (ru) * 2019-08-22 2020-01-24 Общество с ограниченной ответственностью "ЦЕНТР ТРАНСФЕРА БИОТЕХНОЛОГИЙ ОКА-Биотех" ПРИМЕНЕНИЕ ТЕТРААЦЕТИЛИРОВАННОГО 5-АМИНО-4-КАРБАМОИЛИМИДАЗОЛИЛ-1-β-D-РИБОФУРАНОЗИДА В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ Cδ
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK62692D0 (es) * 1992-05-14 1992-05-14 Novo Nordisk As
TW336938B (en) * 1992-05-21 1998-07-21 Pfizer Calcium channel blocking polypeptides from filistata hibernalis
US5773423A (en) * 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists

Also Published As

Publication number Publication date
PL357371A1 (en) 2004-07-26
BG106636A (bg) 2003-01-31
UA73525C2 (en) 2005-08-15
AR029887A1 (es) 2003-07-23
EE200200172A (et) 2003-06-16
HUP0202807A2 (hu) 2002-12-28
IS6286A (is) 2002-02-26
GEP20043241B (en) 2004-05-25
KR100481605B1 (ko) 2005-04-08
CA2386079A1 (en) 2001-04-05
AP2002002458A0 (en) 2002-06-30
DE60024649D1 (de) 2006-01-12
NO20021474L (no) 2002-05-22
IL148222A0 (en) 2002-09-12
PE20010696A1 (es) 2001-07-05
HRP20020253A2 (en) 2004-04-30
WO2001023399A1 (en) 2001-04-05
KR20020034206A (ko) 2002-05-08
PA8503301A1 (es) 2003-06-30
EP1216257B1 (en) 2005-12-07
EP1216257A1 (en) 2002-06-26
TNSN00191A1 (fr) 2005-11-10
EA200200316A1 (ru) 2002-08-29
MY133996A (en) 2007-11-30
SK4182002A3 (en) 2003-04-01
BR0014384A (pt) 2002-07-02
CR6592A (es) 2004-02-23
CZ20021020A3 (cs) 2003-04-16
AU778185B2 (en) 2004-11-18
YU23102A (sh) 2006-01-16
TR200200843T2 (tr) 2002-07-22
JP2003510331A (ja) 2003-03-18
MXPA02003308A (es) 2002-10-04
CN1374967A (zh) 2002-10-16
AU7035200A (en) 2001-04-30
MA26822A1 (fr) 2004-12-20
OA12021A (en) 2006-04-19
ZA200202461B (en) 2003-05-28
ATE312117T1 (de) 2005-12-15
HK1049011A1 (zh) 2003-04-25
NO20021474D0 (no) 2002-03-25
HUP0202807A3 (en) 2005-02-28
EA005422B1 (ru) 2005-02-24
NZ517177A (en) 2003-10-31
GT200000161A (es) 2002-03-22
ECSP003682A (es) 2002-04-23

Similar Documents

Publication Publication Date Title
CO5180581A1 (es) Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
UY26130A1 (es) Compuestos para tratar la obesidad
BR0200782A (pt) Compostos para o tratamento da isquemia
CR20120009A (es) 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728)
CO5090836A1 (es) 3s tetrahidro 3 furanil 1s, 2r 3 / 4 aminofenil sulfonil (isobutil) [amino]1 bencil 2/(fosfonooxi)propilcarbamato de calcio
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
AR024138A1 (es) Inhibidores de la proliferacion celular
PA8462301A1 (es) Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
CY1105953T1 (el) Συνθεσεις για απελευθερωση συνδυασμων φαρμακων
ECSP055609A (es) &#34;Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor&#34;
EA199900303A2 (ru) Замещенные трициклические соединения
CO5070569A1 (es) Compuesto de aminoazol o una sal farmaceuticamente aceptable del mismo y medicamento que los contienen
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
CO5090829A1 (es) Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
CO5271724A1 (es) Uso de agonistas de prostaglandinas para tratar la disfuncion erectil o la impotencia
CO5150178A1 (es) Bromohidrato de eletriptan monohidrato y procedimiento para su preparacion
ES2177811T3 (es) Uso de nitroflavonoides para el tratamiento de la ansiedad.
BR9912816A (pt) Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos
PE20010744A1 (es) Uso de (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol para el tratamiento de la obesidad
CO5160291A1 (es) Composicion farmaceutica topica que contiene 4-(2,4-dihidroxifenil) ciclohexanol
CO5251436A1 (es) Uso de azoles para la prevencion del cancer de piel
CO5221125A1 (es) Inhibidor de intercambiador de sodio hidrogeno de tipo 1
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene

Legal Events

Date Code Title Description
FC Application refused